➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Moodys
Colorcon
Medtronic
McKinsey

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Claims for Patent: 10,261,087

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,261,087
Title:Diagnosis of cancer by detecting auto-antibodies against vascular endothelial growth factor (VEGF)
Abstract: The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against vascular endothelial growth factor (VEGF) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an angiogenesis inhibitor.
Inventor(s): Heidecke; Harald (Berlin, DE), Schulze-Forster; Kai (Berlin, DE)
Assignee: CELLTREND GMBH (Luckenwal, DE)
Application Number:15/115,902
Patent Claims:1. A method for predicting whether a subject to be treated for ovarian cancer with a drug will respond to said treatment, wherein the drug is a VEGF inhibitor selected from the group consisting of bevacizumab and Aflibercept, or wherein the drug is a platinum analogue, the method comprising (i) determining a level of antibodies against vascular endothelial growth factor (VEGF) (anti-VEGF antibodies) in a sample from said subject to be treated, wherein the anti-VEGF antibodies bind to VEGF-A of SEQ ID NO:1; (ii) comparing the determined level of anti-VEGF antibodies in the sample to either one or both of a first and second VEGF antibody control level, a) wherein the first VEGF antibody control level is determined from subjects not showing relapse or progression of ovarian cancer or mortality within 20 months after onset of treatment with said drug, and b) wherein the second VEGF antibody control level is determined from subjects showing relapse or progression of ovarian cancer or mortality within 20 months after onset of treatment with said drug, wherein a decreased level of anti-VEGF antibodies in the sample from the subject to be treated as compared to the first VEGF antibody control level and/or an equal level as compared to the second VEGF antibody control level is indicative for relapse or progression of ovarian cancer or mortality in the subject within 20 months after onset of treatment with said drug, and wherein an increased level of anti-VEGF antibodies in the sample from the subject to be treated as compared to the second VEGF antibody control level and/or an equal level as compared to the first VEGF antibody control level is indicative for no relapse and no progression of ovarian cancer and no mortality in the subject within 20 months after onset of treatment with said drug.

2. The method according to claim 1, wherein the natural logarithm of a level of antibodies against VEGF in the sample from the subject to be treated of less than 0.9 fold as compared to the natural logarithm of the mean of the first VEGF antibody control level is indicative for relapse or progression of ovarian cancer or mortality in the subject within 20 months after onset of treatment with said drug, and/or the natural logarithm of a level of antibodies against VEGF in the sample from the subject to be treated of more than 1.5 fold as compared to the natural logarithm of the mean of the second VEGF antibody control level is indicative for no relapse and no progression of ovarian cancer and no mortality in the subject within 20 months after onset of treatment with said drug.

3. The method according to claim 1, wherein the drug is bevacizumab, cisplatin or carboplatin.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
14153823Feb 4, 2014
PCT Information
PCT FiledFebruary 03, 2015PCT Application Number:PCT/EP2015/052184
PCT Publication Date:August 13, 2015PCT Publication Number:WO2015/117953

Details for Patent 10,261,087

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial CELLTREND GMBH (Luckenwal, DE) 2034-02-04 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial CELLTREND GMBH (Luckenwal, DE) 2034-02-04 RX Orphan search
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18   Start Trial CELLTREND GMBH (Luckenwal, DE) 2034-02-04 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Boehringer Ingelheim
McKinsey
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.